MedPath

Rhythm Training of a Serious Game on the Reading Skills of Children w/ a Specific Learning Disorder Impacting Reading

Not Applicable
Completed
Conditions
Learning Disabilities
Dyslexia
Specific Learning Disorder, With Impairment in Reading
Learning Disorder, Specific
Interventions
Device: control Group - Mila-Placebo
Device: experimental Group - Mila-Learn
Registration Number
NCT05154721
Lead Sponsor
Mila (bMotion Technologies)
Brief Summary

Mila-Learn-01 is a double-blind clinical study (meaning that neither the patient nor the doctor or his/her team will know which game the child has), which enables us to see the effect of a serious game on the child's reading skills.

The patients who will participate in this research will receive, at random, one of the two serious study games, the experimental game (Mila-Learn) or the placebo game (Mila-Placebo). The tasks designed in the placebo game mirror those of Mila-Learn.

Each game comprises eight tasks to be completed on a touchscreen tablet. Each session lasts 25 minutes (±20%); five training sessions lasting 25 minutes are planned per week for eight weeks.

Detailed Description

The study consists of a randomised, double-blind clinical trial with a control group to evaluate the impact of the Mila-Learn game on children's skills. In order to maintain the blinding of the patient and his/her family, the study will be presented to them as evaluating the effect of serious games on a child's learning without explaining that the study is specifically interested in the Mila-Learn game, music and rhythm.

Each child included in the study will be randomised:

* either to the experimental group (EXPE Group) and in this case will receive the Mila-Learn game

* or to the control group (CONT Group) and will receive the Mila-Placebo game.

A randomisation list will be edited by the statistician. It will allow us to know whether the patient will be in the experimental arm or the control arm when sending out the tablets, depending on the chronological order of the inclusions, so that we can send the corresponding tablet to the patient.

In each group, the children will follow the same training protocol consisting of five training sessions per week on the game corresponding to their group. Each game comprises 8 tasks to be completed on a touchscreen tablet. Each session lasts 25 minutes (±20%).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
151
Inclusion Criteria
  • Diagnosis of Specific Learning Disorder with Impairment in Reading through speech therapy testing and confirmed by a doctor. Specific Learning Disorder with Impairment in Reading is defined in the diagnostic and statistical manual of mental disorders (DSM-5).
  • Patient 7-11 years old, schooled from the second year of primary school (CE1) to the last year of primary school (CM2).
  • Native Speaker of French OR French bilingualism at home AND Child schooled in France for more than 3 years
  • Person affiliated with a social security scheme.
  • Participant's agreement to participate and the agreement of the holders of parental authority and commitment to follow the protocol.
Exclusion Criteria
  • Patient undergoing or having undergone speech therapy or psychomotor therapy during the 12 months before the start of the study.
  • Patient who has previously used Mila-Learn.
  • Uncontrolled, chronic illness, at the investigator's discretion.
  • Participation in another interventional study that could impact the analysis of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CONT Groupcontrol Group - Mila-PlaceboThe control group (CONT Group) will receive the Mila-Placebo game.
EXPE Groupexperimental Group - Mila-LearnThe experimental group (EXPE Group) will receive the Mila-Learn game.
Primary Outcome Measures
NameTimeMethod
Evaluation of the effect of musical and rhythmic training measured by the number of pseudo-words correctly read8 weeks after the start of training (T2)

Absolute change in the number of pseudo-words correctly read by the children in the pseudo-word reading test, EVALEO 6-15, by Launay, Maeder, Roustit and Touzin, 2018.

Secondary Outcome Measures
NameTimeMethod
Evaluation of self-esteem measured by the Rosenberg Self-Esteem scale ; using a 4-point scale format ranging from strongly agree to strongly disagree8 weeks after the start of training (T2)

This endpoint relates to the evolution of the child's self-esteem measured by the Rosenberg Self-Esteem scale.

Evaluation of speed and accuracy skills by the percentage of words correctly read in two minutes8 weeks after the start of training (T2)

This endpoint relates to reading skills in terms of speed and accuracy. The analysis will focus on the percentage of words correctly read in two minutes (EVAL2M, Evaleo 6-15).

Evaluation of phonological skills measured by the Battery of Analytical Test on Written Language (BALE) initial or final phoneme deletion test8 weeks after the start of training (T2)

This endpoint relates to the child's phonological skills at T2 compared to T1, evaluated using the BALE \[Battery of Analytical Tests on Written Language\] initial or final phoneme deletion test.

Evaluation of grapheme conversion skills in terms of speed and accuracy measured by two pseudo-word transcription tests8 weeks after the start of training (T2)

This endpoint relates to phoneme-grapheme correspondence skills, evaluated using two pseudo-word transcription tests.

Safety criteriaDuring the training phase, up to 8 weeks

Descriptive evaluation of any adverse events reported by the users.

Evaluation of the reading skills by the children in the pseudo-word reading test, EVALEO 6-1516 weeks after the start of training (T3)

The primary endpoint is the absolute change in the number of pseudo-words correctly read by the children in the pseudo-word reading test, EVALEO 6-15, by Launay, Maeder, Roustit and Touzin, 2018.

Trial Locations

Locations (3)

Centre Hospitalier Henri Laborit

🇫🇷

Poitiers, France

Centre médical pluridisciplinaire CogCharonne

🇫🇷

Paris, France

Hôpital Pitié-Salpêtrière

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath